EU Committee Backs Pfizer-BMS Anti-Clotting Drug

Law360, New York (September 21, 2012, 8:38 PM EDT) -- An advisory committee has recommended that the European Medicines Agency approve an anti-clotting drug for stroke prevention developed by Bristol-Myers Squibb and Pfizer Inc., the companies announced Friday.

The recommendation, from the EMA's Committee for Medicinal Products for Human Use, will be reviewed by European regulators. If they adopt the recommendation, the drug, Eliquis, will be approved throughout the European Union, as well as Iceland and Norway, the companies said.

Eliquis, known by the generic name apixaban, is already approved in Europe for the prevention of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.